Defence Therapeu - DTCFF STOCK NEWS

Defence Therapeutics has received a 30-day extension from the Canadian Securities Exchange for its non-brokered private placement offering. The company previously closed a first tranche of 1,550,000 units at $0.50 per unit, raising $775,000. The upcoming financing will partially fund the development of Defence's preclinical radiopharmaceuticals and ADC programs, which utilize their proprietary Accum® technology platform. Both programs aim to enhance cancer treatment efficacy by delivering radioactivity/drugs more precisely to cancer cells, potentially reducing dosing requirements and side effects for patients.

Defence Therapeutics has completed the first tranche of its non-brokered private placement, raising $775,000 through the sale of units at $0.50 each. Each unit comprises one common share and half a warrant, with each whole warrant exercisable at $1.00 per share within 24 months. The company paid $14,000 in finder's fees and issued 28,000 finder's warrants. The proceeds will support preclinical and clinical programs and working capital. All securities are subject to a four-month hold period.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) announces corporate updates and financing plans. Key points include:

1. Sebastien Plouffe returns as CEO, replacing Kwin Grauer.

2. New board appointments: Dr. Philippe Lefrançois and Mr. Arnab De.

3. Dr. Moutih Rafei steps down from the board but remains CSO.

4. Joseph Meagher leaves the board but stays as CFO during transition to Arnab De.

5. 200,000 stock options granted to new directors at $0.60 per share.

6. Non-brokered private placement announced for up to $3 million at $0.50 per unit, with each unit including one common share and half a warrant.

7. Proceeds to be used for advancing preclinical and clinical programs, and working capital.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) has announced a leadership change as it transitions from preclinical to clinical stage. Kwin Grauer has been appointed as the interim Chief Executive Officer, replacing Sébastien Plouffe. Grauer, who joined the company's Board of Directors in December 2022, brings over 20 years of experience in operating, buying, and selling small and medium-sized businesses.

Grauer is a CPA, CA with expertise in financing, financial modeling, and corporate restructuring. He has served on the Board of Langara College, including roles as Chair of the Finance and Audit Committee and Board Chair. Plouffe will continue to serve as a director of Defence Therapeutics, with the company acknowledging his contributions to its growth and development.

Defence Therapeutics Inc. (DTCFF) is exploring the potential of its Accum® technology to enhance the efficacy of GLP-1 agonists in treating obesity and type 2 diabetes. The company aims to develop a formulation that improves the in vivo stability, distribution, tolerability, and activity of GLP-1 analogs.

This initiative addresses the growing global obesity crisis, with over 4 billion people expected to be overweight or obese by 2035. Current GLP-1 analogs face challenges such as gastrointestinal side effects, injection management, and patient compliance. Defence's Accum® technology could potentially overcome these limitations by acting as a protective nanocarrier.

The GLP-1 receptor agonist market is projected to reach US$125 billion by 2033, highlighting the significant opportunity in this therapeutic area.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) has announced an update on its collaboration with Orano Support SAS to develop a novel Radio-Immuno-Conjugate (RIC) for cancer treatment. The project aims to create a next-generation RIC using Auger electron (AE) emitter elements combined with Defence's Accum® technology.

The Accum® technology addresses key limitations of RICs, such as endosomal sequestration and poor nuclear accumulation. Defence has developed various Accum® variants with different properties and has secured their production. The company has also patented the ability of some Accum® variants to deliver antibodies or antibody-conjugates into the nucleus.

Defence has arranged for in vitro and in vivo preclinical studies to be conducted by the radiopharmaceuticals team at the Canadian Nuclear Laboratories. This collaboration aims to open a new cancer therapy market based on promising radiotherapeutics using AE emitter radionuclides.

Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) has been approved for the Canadian Nuclear Research Initiative Health (CNRI-H) Program by Canadian Nuclear Laboratories (CNL). This collaboration aims to accelerate Defence's radio-immuno-conjugates project, focusing on novel 111In-AccuTOX®-Trastuzumab constructs.

The project's objectives include:

• Synthesizing and evaluating constructs to demonstrate AccuTOX®'s role in evading endosome entrapment
• Ensuring nuclear localization for 111In to emit Auger Electrons
• Developing constructs lethal to HER2-positive cancer cells
• Identifying a potent 111In-AccuTOX®-Trastuzumab molecule for treating solid tumors resistant to current HER2-targeting therapies

The global radiopharmaceuticals market is projected to reach $21.8 billion by 2033, with a CAGR of 10.6% from 2024 to 2033.

Defence Therapeutics has received a No Objection Letter (NOL) from Health Canada for its Phase I clinical trial of ACCUM-002 (AccuTOX) for treating unresectable Stage IIIB and IV melanoma. The trial, designated ACCUM-002-01, will assess the safety and tolerability of intratumoral administration of AccuTOX, both as a monotherapy and combined with the LAG-3 checkpoint inhibitor relatlimab and PD-1 inhibitor nivolumab (Opdualag). Secondary objectives include collecting preliminary efficacy data and determining the Maximum Tolerated Dose (MTD) and recommended Phase 2 Dose (RP2D). The trial is expected to be conducted in hospitals in Quebec and Ontario. According to Vision Research Reports, the global cancer immunotherapy market is projected to grow significantly, reaching USD 280.11 billion by 2033, with a CAGR of 8.34% from 2024 to 2033.

Defence Therapeutics (CSE: DTC, OTCQB: DTCFF) has announced that its Accum-002™ (AccuTOX®) exhibits dual functionality: acting as a tumor-killing molecule and an immune booster. AccuTOX® works synergistically with Immune Checkpoint Inhibitors (ICI) to enhance the immune system's capability to recognize and attack tumors. This is particularly significant as many solid tumors create a 'cold' environment that impedes immune response, leading to low success rates in ICI treatments. AccuTOX® transforms these cold tumors into 'hot' tumors, significantly increasing the effectiveness of ICIs. Preclinical studies showed a tenfold increase in efficacy when AccuTOX® is combined with various ICIs. Defence is open to partnerships to further develop this promising treatment.